BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20482381)

  • 1. A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples.
    Wu S; Zhu Z; He J; Luo X; Xu J; Ren-Heidenreich L
    Clin Chem Lab Med; 2010 Aug; 48(8):1103-6. PubMed ID: 20482381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
    Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
    Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
    Chang YS; Er TK; Lu HC; Yeh KT; Chang JG
    Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer.
    Li J; Gan S; Blair A; Min K; Rehage T; Hoeppner C; Halait H; Brophy VH
    Arch Pathol Lab Med; 2019 Feb; 143(2):183-189. PubMed ID: 30088781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
    Ausch C; Buxhofer-Ausch V; Oberkanins C; Holzer B; Minai-Pour M; Jahn S; Dandachi N; Zeillinger R; Kriegshäuser G
    J Mol Diagn; 2009 Nov; 11(6):508-13. PubMed ID: 19797612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
    Okayama N; Nishioka M; Hazama S; Sakai K; Suehiro Y; Maekawa M; Sakamoto J; Iwamoto S; Kato T; Mishima H; Oka M; Hinoda Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):165-71. PubMed ID: 20926413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology.
    Zhang L; Yang H; Zhao Y; Liu W; Wu S; He J; Luo X; Zhu Z; Xu J; Zhou Q; Ren-Heidenreich L
    Curr Drug Metab; 2012 Sep; 13(7):1007-11. PubMed ID: 22591345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.
    Ogasawara N; Bando H; Kawamoto Y; Yoshino T; Tsuchihara K; Ohtsu A; Esumi H
    Jpn J Clin Oncol; 2011 Jan; 41(1):52-6. PubMed ID: 20696815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Screening for K-ras mutations in colorectal and lung cancers by using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing].
    Zhang HP; Fu L; Chen PQ; Ye YB; Ji TH; Zheng LM
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):757-61. PubMed ID: 21215167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
    Weyn C; Van Raemdonck S; Dendooven R; Maes V; Zwaenepoel K; Lambin S; Pauwels P
    BMC Cancer; 2017 Feb; 17(1):139. PubMed ID: 28201998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.
    Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N; Sato A; Miki Y; Kitera K; Hirai M; Hatake K; Kimura S; Sueoka-Aragane N
    Pathol Oncol Res; 2017 Oct; 23(4):737-744. PubMed ID: 28058585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
    Jänne PA; Borras AM; Kuang Y; Rogers AM; Joshi VA; Liyanage H; Lindeman N; Lee JC; Halmos B; Maher EA; Distel RJ; Meyerson M; Johnson BE
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):751-8. PubMed ID: 16467085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis.
    Ma ES; Wong CL; Law FB; Chan WK; Siu D
    J Clin Pathol; 2009 Oct; 62(10):886-91. PubMed ID: 19783717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
    Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    Darwanto A; Hein AM; Strauss S; Kong Y; Sheridan A; Richards D; Lader E; Ngowe M; Pelletier T; Adams D; Ricker A; Patel N; Kühne A; Hughes S; Shiffman D; Zimmermann D; Te Kaat K; Rothmann T
    BMC Cancer; 2017 May; 17(1):358. PubMed ID: 28532404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues.
    Becker K; Vollbrecht C; Koitzsch U; Koenig K; Fassunke J; Huss S; Nuernberg P; Heukamp LC; Buettner R; Odenthal M; Altmueller J; Merkelbach-Bruse S
    J Clin Pathol; 2013 Sep; 66(9):803-6. PubMed ID: 23618693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens.
    Gallegos Ruiz MI; Floor K; Rijmen F; Grünberg K; Rodriguez JA; Giaccone G
    Cell Oncol; 2007; 29(3):257-64. PubMed ID: 17452778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues.
    Dufort S; Richard MJ; de Fraipont F
    Anal Biochem; 2009 Aug; 391(2):166-8. PubMed ID: 19464247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.